Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Политаблетка в профилактике сердечно-сосудистых заболеваний: доказательная база, ограничения и перспективы (по материалам доклада Европейского общества по артериальной гипертензии)
________________________________________________
Morozova T.E., Yudina I.Yu., Karnoukh K.I., Shatskiy D.A. Polypill in the prevention of cardiovascular diseases: evidence base, limitations and prospects (based on the report of the European Society for Hypertension). Consilium Medicum. 2017; 19 (10): 8–12. DOI: 10.26442/2075-1753_19.10.8-12
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: политаблетка, полипилюля, приверженность, факторы риска, артериальная гипертензия, профилактика, комбинированная терапия.
________________________________________________
The article discusses the evidence base, limitations and prospects for the use of combined multicomponent drugs in the prevention of cardiovascular diseases. Complex of antihypertensive, lipid-lowering, hypoglycemic and antiplatelet therapy significantly reduces the risk of cardiovascular complications and fatal events. However, in real clinical practice, a full implementation of all these approaches is not always carried out, which reduces the effectiveness of preventing cardiovascular diseases.
Key words: poly-drug, polypill, adherence, risk factors, arterial hypertension, prevention, combined therapy.
2. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2–3.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
4. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147–52.
5. Corrao G, Conti V, Merlino L et al. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010; 32: 300–10.
6. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200–9.
7. Wang TD, Chen YH, Huang CH et al. Bidirectional adherence changes and associated factors in patients switched from free combinations to equivalent single-pill combinations of antihypertensive drugs. Hypertension 2014; 63: 958–67.
8. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64: 1279–83.
9. Brambilla G, Bombelli M, Seravalle G et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BPCARE study. J Hypertens 2013; 31: 2018–24.
10. Kotseva K, Wood D, De Backer G et al, EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–37.
11. Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25: 1491–8.
12. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
13. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27: 1509–20.
14. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028–35.
15. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 533–7.
16. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214–26.
17. Corrao G, Parodi A, Nicotra F et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610–8.
18. Corrao G, Rea F, Ghirardi A et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66: 742–9.
19. Corrao G, Ibrahim B, Nicotra F et al. Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis 2013; 230: 171–6.
20. Hameed MA, Dasgupta I, Gill P. Poor adherence to antihypertensive drugs. BMJ 2016; 354: i3268.
21. Mancia G, Zambon A, Soranna D et al. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens 2014; 32: 1708–15.
22. Holmes HM, Luo R, Hanlon JT et al. Ethnic disparities in adherence to antihypertensive medications of Medicare part D beneficiaries. J Am Geriatr Soc 2012; 60: 1298–303.
23. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
24. Sinnott SJ, Buckley C, O’Riordan D et al. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One 2013; 8:e64914.
25. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55: 399–407.
26. Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 2015; 116: 1058–73.
27. Yusuf S, Pais P, Sigamani A et al. Comparison of risk actor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012; 5: 463–71.
28. Thom S, Poulter N, Field J et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918–29.
29. Selak V, Elley CR, Bullen C et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomized controlled trial in primary care. BMJ 2014; 348: g3318.
30. Patel A, Cass A, Peiris D et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920–30.
31. Рolypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014; 64: 2071–82.
32. Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention. Int J Cardiol 2015; 201 (Suppl 1): S15–S22.
33. Kolte D, Aronow WS, Banach M. Polypills for the prevention of cardiovascular diseases. Expert Opin Investig Drugs 2016; 22: 1–10.
34. Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med 2009; 6: 112–9.
35. Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran). Available at: http://clinicaltrials. gov/ct2/show/NCT01271985.
36. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk – overview and meta-analyses of randomized trials. J Hypertens 2014; 32: 23052314.
37. Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet 2017; 389: 1055–65.
________________________________________________
1. World Health Organization. Secondary prevention of noncommunicable disease in low and middle income countries through communitybased and health service interventions. WHO – Wellcome Trust Meeting report 1–3. Geneva: World Health Organization; 2002.
2. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002; 360: 2–3.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
4. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165: 1147–52.
5. Corrao G, Conti V, Merlino L et al. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy. Clin Ther 2010; 32: 300–10.
6. DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42: 200–9.
7. Wang TD, Chen YH, Huang CH et al. Bidirectional adherence changes and associated factors in patients switched from free combinations to equivalent single-pill combinations of antihypertensive drugs. Hypertension 2014; 63: 958–67.
8. Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm 2007; 64: 1279–83.
9. Brambilla G, Bombelli M, Seravalle G et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BPCARE study. J Hypertens 2013; 31: 2018–24.
10. Kotseva K, Wood D, De Backer G et al, EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–37.
11. Volpe M, Tocci G, Trimarco B et al. Blood pressure control in Italy: results of recent surveys on hypertension. J Hypertens 2007; 25: 1491–8.
12. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
13. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens 2009; 27: 1509–20.
14. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028–35.
15. Hughes D, McGuire A. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension. J Hum Hypertens 1998; 12: 533–7.
16. McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214–26.
17. Corrao G, Parodi A, Nicotra F et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610–8.
18. Corrao G, Rea F, Ghirardi A et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015; 66: 742–9.
19. Corrao G, Ibrahim B, Nicotra F et al. Long-term use of statins reduces the risk of hospitalization for dementia. Atherosclerosis 2013; 230: 171–6.
20. Hameed MA, Dasgupta I, Gill P. Poor adherence to antihypertensive drugs. BMJ 2016; 354: i3268.
21. Mancia G, Zambon A, Soranna D et al. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens 2014; 32: 1708–15.
22. Holmes HM, Luo R, Hanlon JT et al. Ethnic disparities in adherence to antihypertensive medications of Medicare part D beneficiaries. J Am Geriatr Soc 2012; 60: 1298–303.
23. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
24. Sinnott SJ, Buckley C, O’Riordan D et al. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One 2013; 8:e64914.
25. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a metaanalysis. Hypertension 2010; 55: 399–407.
26. Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 2015; 116: 1058–73.
27. Yusuf S, Pais P, Sigamani A et al. Comparison of risk actor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (Polycap) in individuals at high risk of cardiovascular diseases the Second Indian Polycap Study (TIPS-2) investigators. Circ Cardiovasc Qual Outcomes 2012; 5: 463–71.
28. Thom S, Poulter N, Field J et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013; 310: 918–29.
29. Selak V, Elley CR, Bullen C et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomized controlled trial in primary care. BMJ 2014; 348: g3318.
30. Patel A, Cass A, Peiris D et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2015; 22: 920–30.
31. Рolypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014; 64: 2071–82.
32. Tamargo J, Castellano JM, Fuster V. The Fuster-CNIC-Ferrer cardiovascular polypill: a polypill for secondary cardiovascular prevention. Int J Cardiol 2015; 201 (Suppl 1): S15–S22.
33. Kolte D, Aronow WS, Banach M. Polypills for the prevention of cardiovascular diseases. Expert Opin Investig Drugs 2016; 22: 1–10.
34. Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med 2009; 6: 112–9.
35. Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill (PolyIran). Available at: http://clinicaltrials. gov/ct2/show/NCT01271985.
36. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk – overview and meta-analyses of randomized trials. J Hypertens 2014; 32: 23052314.
37. Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet 2017; 389: 1055–65.
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*temorozova@gmail.com
________________________________________________
T.E.Morozova*, I.Yu.Yudina, K.I.Karnoukh, D.A.Shatskiy
I.M.Sechenov First Moscow Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*temorozova@gmail.com